Medidata Blog

June 24 Media Roundup

Reading Time: < 1 minute

Here’s what you missed in recent industry news. Follow us on Twitter and LinkedIn for the latest in how technology is transforming life sciences.

Free genetic testing for cancer patients.

Celebrating the first ever United State of Women Summit as White House commits $50 million to improve lives of women worldwide.

Pfizer and Big Pharma are making clinical trials more efficient with tech platforms.

Microbubbles and ultrasonic waves: opening the blood-brain barrier may change the way we treat cancer and Alzheimer’s.

Stem cell factory? Researchers in Boston are working to manufacture beta cells to treat type 1 diabetes.

Pharma joins the fight against superbugs.

Stat News chats with Bill Gates on public health, biotech and the cancer moonshot.

Biggest opportunity in health IT? The market for population health managementis expected to increase 284% in the next five years.

Break out the dumbbells. Research shows exercise helps solidify memories.

Think test drives are just for cars? VR tech is allowing surgeons to get a 3-D simulation of a patient’s brain.

MIT researchers are pioneering new 3-D printing methods with potential for sensors.

La Roche-Posay launched the first stretchable electronic for consumers measuring sun exposure.

Drug development, precision medicine and alternative intelligence.

A new breakthrough in breast and ovarian cancer research for women with BRCA1 gene mutations, which affects 1 in 1,000 women.

On our radar – the U.S. Senate is set to review the 21st Century Cures Act to speed drug approvals.

TechCrunch explores why the pharma industry has yet to adopt genomics in drug development programs.

U.S. FDA approved the first Zika vaccine for human clinical trials.

Duke Clinical Research Institute (DCRI) has partnered with analytics firm SAS and released 45 years of cardiovascular data for secondary analysis. DCRI is the first outside organization to share data with the “dirtiness of the real world” on this scale, making it broader than “sterile” trial data that only represents a subset of the population.

Geeks Talk Clinical